Developer docs
API playgroundTry for free, no card

Search company profiles

Terns Pharmaceuticals

Full company profile

uuid00007wd

Namestring
Terns Pharmaceuticals
Legal namestring
Terns Pharmaceuticals, Inc.
Websiteurl
ternspharma.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Terns Pharmaceuticals, Inc. was a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Foster City (also referenced as San Mateo), California, that developed oral small-molecule therapies for chronic diseases spanning oncology and metabolic disorders. The company's pipeline comprised four investigational assets: TERN-701, a novel allosteric BCR::ABL1 tyrosine kinase inhibitor in Phase 1/2 development (CARDINAL trial) for adults with Philadelphia chromosome-positive chronic myeloid leukemia (CML) who have failed two or more prior tyrosine kinase inhibitors; TERN-601, an oral small molecule GLP-1 receptor agonist in first-in-human studies for obesity; TERN-501, a highly selective thyroid hormone receptor β agonist that completed a Phase 2a trial (DUET) in metabolic dysfunction-associated steatohepatitis (MASH) as monotherapy and in combination with TERN-101; and TERN-101, a nonsteroidal farnesoid X receptor (FXR) agonist evaluated in the same DUET trial. TERN-701 received FDA Orphan Drug Designation in March 2024 and FDA Breakthrough Therapy Designation in April 2026.

Terns operated a pre-commercial business model with no approved products and no product revenue. The company funded operations entirely through public equity financings, completing cumulative gross proceeds of approximately $865 million across four public offerings (August 2022 ~$65 million, September 2024 ~$150 million, December 2025 $650 million), following earlier venture financing rounds from investors including Deerfield, Eli Lilly, Lilly Asia Ventures, OrbiMed, Vivo Capital, and Decheng Capital. Its go-to-market motion centered on scientific engagement and clinical evidence generation rather than commercial sales: medical affairs outreach, peer-reviewed publications (including Nature Medicine, June 2025), and presentations at major hematology, oncology, diabetes, and hepatology congresses (ASH, SOHO, EHA, ADA, EASD, EASL, AASLD, Keystone).

On March 25, 2026, Merck & Co. announced a definitive agreement to acquire Terns for approximately $6.7 billion ($53.00 per share in cash), and the transaction closed on May 5, 2026, with approximately 86.36% of shares validly tendered, making Terns a wholly-owned subsidiary of Merck. The acquisition provided Merck access to the full pipeline, with the strategic rationale linked to expanding Merck's oncology and hematology pipeline ahead of Keytruda's patent expiration in 2028. Prior to acquisition, Amy L. Burroughs served as CEO; Andrew Gengos served as CFO (departing after the acquisition).

Short descriptiontext

Terns Pharmaceuticals was a clinical-stage biopharmaceutical company developing oral small-molecule therapies for chronic myeloid leukemia, obesity, and MASH. Its lead asset TERN-701 received FDA Breakthrough Therapy Designation. Terns was acquired by Merck & Co. in May 2026 for ~$6.7 billion.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersFoster City, United States
HQ citystring
Foster City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small molecule therapeutics, tyrosine kinase inhibitors, chronic myeloid leukemia, GLP-1 receptor agonists, liver disease treatments
Industry3 codes
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAI
Hematology Specialty Pharmaceuticals (Non-malignant)
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Biopharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-commercial Pipeline / No Revenue
TypeSubscription Recurring
Description

Terns Pharmaceuticals was a clinical-stage biopharmaceutical company with no approved products and no commercial revenue at the time of its acquisition. The company was entirely dependent on public equity financings and ultimately a strategic acquisition to fund its R&D operations. All value was derived from the clinical development stage of its pipeline candidates.

pharmiweb.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Terns Pharmaceuticals was a clinical-stage biopharmaceutical company developing a pipeline of oral small-molecule drug candidates targeting chronic myeloid leukemia (TERN-701, an allosteric BCR::ABL1 inhibitor), obesity (TERN-601, an oral GLP-1 receptor agonist), and metabolic dysfunction-associated steatohepatitis or MASH (TERN-501, a selective THR-β agonist, and TERN-101, a nonsteroidal FXR agonist). The company had no approved or commercially marketed products, with all candidates in investigational stages of clinical development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • TERN-701 Phase 1/2 CARDINAL trial: Major molecular response and deep molecular response rates at week 24 in patients with previously treated CML; majority of adverse events were low grade with a favorable safety profile.
+2 more records
Product overview1 text field

Terns Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing oral therapies for liver diseases and cancer. The company developed a pipeline of drug candidates including TERN-701 (an allosteric BCR::ABL1 inhibitor for chronic myeloid leukemia), TERN-601 (a GLP-1 receptor agonist for obesity), TERN-501 (a thyroid hormone receptor β agonist for MASH), and TERN-101 (an FXR agonist for MASH). Effective May 5, 2026, Terns Pharmaceuticals became a wholly owned subsidiary of Merck & Co., Inc.

Product and service4 records
1TERN-701
CategoryDrug Candidate - Oncology
Description

Investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor in Phase 1/2 CARDINAL clinical development for adults with Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase who have failed at least two prior tyrosine kinase inhibitors, including those with T315I resistance mutation.

2TERN-601
CategoryDrug Candidate - Metabolic Disease
Description

Investigational oral small-molecule GLP-1 receptor agonist in clinical development for the treatment of obesity, with no effect of food or proton pump inhibitors on pharmacokinetics observed in first-in-human studies.

3TERN-501
CategoryDrug Candidate - Metabolic Liver Disease
Description

Investigational highly selective thyroid hormone receptor β (THR-β) agonist that completed a Phase 2a DUET clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), demonstrating significant reductions in MRI-based liver fat content and fibroinflammation as monotherapy and in combination with TERN-101.

4TERN-101
CategoryDrug Candidate - Metabolic Liver Disease
Description

Investigational nonsteroidal farnesoid X receptor (FXR) agonist evaluated in combination with TERN-501 in the Phase 2a DUET trial for metabolic dysfunction-associated steatohepatitis (MASH), demonstrating combinatorial effects on liver fat and fibrosis markers.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-03-25
Description

Merck & Co. announced a definitive agreement on March 25, 2026, to acquire Terns Pharmaceuticals for approximately $6.7 billion ($53.00 per share in cash), acquiring all outstanding shares through a cash tender offer. The acquisition was completed on May 5, 2026, making Terns a wholly owned subsidiary of Merck. Merck gained access to Terns' full pipeline including TERN-701 (allosteric BCR::ABL1 inhibitor for CML), TERN-601 (oral GLP-1 RA for obesity), TERN-501 (THR-β agonist for MASH), and TERN-101 (FXR agonist for MASH). The deal supported Merck's strategy to expand its oncology and hematology pipeline ahead of Keytruda's patent expiration in 2028.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Novartis markets asciminib (Scemblix), the FDA-approved allosteric BCR::ABL1 inhibitor that directly competes with TERN-701 in chronic myeloid leukemia. Both companies target the same allosteric binding site and the same 2L+ CML patient population.

TypeDirect peer
Description

Madrigal developed resmetirom (Rezdiffra), the first FDA-approved THR-β agonist for MASH — the same mechanism class as TERN-501. Both companies target metabolic dysfunction-associated steatohepatitis with selective thyroid hormone receptor β agonism.

TypeBroad incumbent
Description

Lilly is a prior Terns investor (Lilly Asia Ventures participated in 2018 and 2021 rounds) and develops orforglipron, an oral small molecule GLP-1 RA that directly competes with TERN-601, plus dominant injectable incretins (Mounjaro/Zepbound). Comparable in metabolic and obesity pipeline focus.

TypeEmerging player
Description

Structure Therapeutics is a clinical-stage biotech developing oral small molecule GLP-1 receptor agonists for obesity, directly competing with Terns' TERN-601. Both companies target the same oral GLP-1 differentiation vs. injectable peptide incumbents.

TypeEmerging player
Description

Viking Therapeutics is a clinical-stage metabolic biotech developing oral and injectable obesity/MASH therapies, including VK2735 (GLP-1/GIP) and an oral formulation. Comparable pipeline breadth and focus on cardiometabolic disease overlap with Terns' TERN-501 and TERN-601.

TypeBroad incumbent
Description

Pfizer developed danuglipron, an oral small molecule GLP-1 RA that competed directly with Terns' TERN-601 in obesity. Both companies target oral administration as the key differentiator vs. injectable peptide GLP-1s.

TypeEmerging player
Description

Syndax is a clinical-stage small molecule oncology biotech with a comparable capitalization profile to Terns prior to acquisition and a similar model of developing differentiated targeted therapies. Both companies share a small-team, clinical-stage biotech operational profile.

8Nuvalent
TypeEmerging player
Description

Nuvalent is a clinical-stage precision oncology biotech developing next-generation kinase inhibitors with novel binding modes — directly analogous to Terns' allosteric BCR::ABL1 approach with TERN-701. Both companies emphasize mechanism-based differentiation from approved kinase inhibitors.

TypeDirect peer
Description

Akero is developing efruxifermin (an Fc-FGF21 analog) for MASH, directly competing with Terns' TERN-501 in the metabolic dysfunction-associated steatohepatitis indication. Both companies target late-stage MASH with novel mechanisms.

TypeEmerging player
Description

Deciphera was a clinical-stage small molecule oncology biotech that developed novel kinase inhibitors and was acquired by Bayer for ~$2.4B in 2021. Comparable development-stage model and kinase inhibitor focus to Terns, with prior strategic-acquisition precedent.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Terns Pharmaceuticals

Clinical-Stage Biopharmaceuticalsternspharma.com

Terns Pharmaceuticals was a clinical-stage biopharmaceutical company developing oral small-molecule therapies for chronic myeloid leukemia, obesity, and MASH. Its lead asset TERN-701 received FDA Breakthrough Therapy Designation. Terns was acquired by Merck & Co. in May 2026 for ~$6.7 billion.

What Terns Pharmaceuticals does

Terns Pharmaceuticals, Inc. was a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Foster City (also referenced as San Mateo), California, that developed oral small-molecule therapies for chronic diseases spanning oncology and metabolic disorders. The company's pipeline comprised four investigational assets: TERN-701, a novel allosteric BCR::ABL1 tyrosine kinase inhibitor in Phase 1/2 development (CARDINAL trial) for adults with Philadelphia chromosome-positive chronic myeloid leukemia (CML) who have failed two or more prior tyrosine kinase inhibitors; TERN-601, an oral small molecule GLP-1 receptor agonist in first-in-human studies for obesity; TERN-501, a highly selective thyroid hormone receptor β agonist that completed a Phase 2a trial (DUET) in metabolic dysfunction-associated steatohepatitis (MASH) as monotherapy and in combination with TERN-101; and TERN-101, a nonsteroidal farnesoid X receptor (FXR) agonist evaluated in the same DUET trial. TERN-701 received FDA Orphan Drug Designation in March 2024 and FDA Breakthrough Therapy Designation in April 2026.

Terns operated a pre-commercial business model with no approved products and no product revenue. The company funded operations entirely through public equity financings, completing cumulative gross proceeds of approximately $865 million across four public offerings (August 2022 ~$65 million, September 2024 ~$150 million, December 2025 $650 million), following earlier venture financing rounds from investors including Deerfield, Eli Lilly, Lilly Asia Ventures, OrbiMed, Vivo Capital, and Decheng Capital. Its go-to-market motion centered on scientific engagement and clinical evidence generation rather than commercial sales: medical affairs outreach, peer-reviewed publications (including Nature Medicine, June 2025), and presentations at major hematology, oncology, diabetes, and hepatology congresses (ASH, SOHO, EHA, ADA, EASD, EASL, AASLD, Keystone).

On March 25, 2026, Merck & Co. announced a definitive agreement to acquire Terns for approximately $6.7 billion ($53.00 per share in cash), and the transaction closed on May 5, 2026, with approximately 86.36% of shares validly tendered, making Terns a wholly-owned subsidiary of Merck. The acquisition provided Merck access to the full pipeline, with the strategic rationale linked to expanding Merck's oncology and hematology pipeline ahead of Keytruda's patent expiration in 2028. Prior to acquisition, Amy L. Burroughs served as CEO; Andrew Gengos served as CFO (departing after the acquisition).

Terns Pharmaceuticals firmographics

Firmographics
Name
Terns Pharmaceuticals
Legal name
Terns Pharmaceuticals, Inc.
Website
https://ternspharma.com
Company type
Public
Founded year
2017
Operating status
Acquired
Headcount range
51–100 employees
Short description
Terns Pharmaceuticals was a clinical-stage biopharmaceutical company developing oral small-molecule therapies for chronic myeloid leukemia, obesity, and MASH. Its lead asset TERN-701 received FDA Breakthrough Therapy Designation. Terns was acquired by Merck & Co. in May 2026 for ~$6.7 billion.
Ownership category
akta.pro rank

Terns Pharmaceuticals industry classification

Industry
Product category
Clinical-Stage Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAI
Hematology Specialty Pharmaceuticals (Non-malignant)
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Small molecule therapeutics
  • Tyrosine kinase inhibitors
  • Chronic myeloid leukemia
  • GLP-1 receptor agonists
  • Liver disease treatments

Where Terns Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Foster City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Terns Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pre-commercial Pipeline / No Revenue: Terns Pharmaceuticals was a clinical-stage biopharmaceutical company with no approved products and no commercial revenue at the time of its acquisition. The company was entirely dependent on public equity financings and ultimately a strategic acquisition to fund its R&D operations. All value was derived from the clinical development stage of its pipeline candidates.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Terns Pharmaceuticals product offering

Product offering

Core offering

Terns Pharmaceuticals was a clinical-stage biopharmaceutical company developing a pipeline of oral small-molecule drug candidates targeting chronic myeloid leukemia (TERN-701, an allosteric BCR::ABL1 inhibitor), obesity (TERN-601, an oral GLP-1 receptor agonist), and metabolic dysfunction-associated steatohepatitis or MASH (TERN-501, a selective THR-β agonist, and TERN-101, a nonsteroidal FXR agonist). The company had no approved or commercially marketed products, with all candidates in investigational stages of clinical development.

Product overview

Terns Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing oral therapies for liver diseases and cancer. The company developed a pipeline of drug candidates including TERN-701 (an allosteric BCR::ABL1 inhibitor for chronic myeloid leukemia), TERN-601 (a GLP-1 receptor agonist for obesity), TERN-501 (a thyroid hormone receptor β agonist for MASH), and TERN-101 (an FXR agonist for MASH). Effective May 5, 2026, Terns Pharmaceuticals became a wholly owned subsidiary of Merck & Co., Inc.

Differentiator

Problem solved

Functional benefit

Products and services

  • TERN-701 Investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor in Phase 1/2 CARDINAL clinical development for adults with Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase who have failed at least two prior tyrosine kinase inhibitors, including those with T315I resistance mutation.
  • TERN-601 Investigational oral small-molecule GLP-1 receptor agonist in clinical development for the treatment of obesity, with no effect of food or proton pump inhibitors on pharmacokinetics observed in first-in-human studies.
  • TERN-501 Investigational highly selective thyroid hormone receptor β (THR-β) agonist that completed a Phase 2a DUET clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), demonstrating significant reductions in MRI-based liver fat content and fibroinflammation as monotherapy and in combination with TERN-101.
  • TERN-101 Investigational nonsteroidal farnesoid X receptor (FXR) agonist evaluated in combination with TERN-501 in the Phase 2a DUET trial for metabolic dysfunction-associated steatohepatitis (MASH), demonstrating combinatorial effects on liver fat and fibrosis markers.

Quantifiable outcome

  • TERN-701 Phase 1/2 CARDINAL trial: Major molecular response and deep molecular response rates at week 24 in patients with previously treated CML; majority of adverse events were low grade with a favorable safety profile.
  • +2 more outcomes

Companies that use Terns Pharmaceuticals

Customer profile

Segments3 records

Ideal customer profiles2 records

Terns Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Terns Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Merck & Co., Inc. (MSD outside US and Canada)flagshipStrategic or Co-development Partner · 25 March 2026Merck & Co. announced a definitive agreement on March 25, 2026, to acquire Terns Pharmaceuticals for approximately $6.7 billion ($53.00 per share in cash), acquiring all outstanding shares through a cash tender offer. The acquisition was completed on May 5, 2026, making Terns a wholly owned subsidiary of Merck. Merck gained access to Terns' full pipeline including TERN-701 (allosteric BCR::ABL1 inhibitor for CML), TERN-601 (oral GLP-1 RA for obesity), TERN-501 (THR-β agonist for MASH), and TERN-101 (FXR agonist for MASH). The deal supported Merck's strategy to expand its oncology and hematology pipeline ahead of Keytruda's patent expiration in 2028.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

Terns Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Novartis: Novartis markets asciminib (Scemblix), the FDA-approved allosteric BCR::ABL1 inhibitor that directly competes with TERN-701 in chronic myeloid leukemia. Both companies target the same allosteric binding site and the same 2L+ CML patient population.
  • Madrigal Pharmaceuticals: Madrigal developed resmetirom (Rezdiffra), the first FDA-approved THR-β agonist for MASH — the same mechanism class as TERN-501. Both companies target metabolic dysfunction-associated steatohepatitis with selective thyroid hormone receptor β agonism.
  • Akero Therapeutics: Akero is developing efruxifermin (an Fc-FGF21 analog) for MASH, directly competing with Terns' TERN-501 in the metabolic dysfunction-associated steatohepatitis indication. Both companies target late-stage MASH with novel mechanisms.

Broad incumbents

  • Eli Lilly: Lilly is a prior Terns investor (Lilly Asia Ventures participated in 2018 and 2021 rounds) and develops orforglipron, an oral small molecule GLP-1 RA that directly competes with TERN-601, plus dominant injectable incretins (Mounjaro/Zepbound). Comparable in metabolic and obesity pipeline focus.
  • Pfizer: Pfizer developed danuglipron, an oral small molecule GLP-1 RA that competed directly with Terns' TERN-601 in obesity. Both companies target oral administration as the key differentiator vs. injectable peptide GLP-1s.

Emerging players

  • Structure Therapeutics: Structure Therapeutics is a clinical-stage biotech developing oral small molecule GLP-1 receptor agonists for obesity, directly competing with Terns' TERN-601. Both companies target the same oral GLP-1 differentiation vs. injectable peptide incumbents.
  • Viking Therapeutics: Viking Therapeutics is a clinical-stage metabolic biotech developing oral and injectable obesity/MASH therapies, including VK2735 (GLP-1/GIP) and an oral formulation. Comparable pipeline breadth and focus on cardiometabolic disease overlap with Terns' TERN-501 and TERN-601.
  • Syndax Pharmaceuticals: Syndax is a clinical-stage small molecule oncology biotech with a comparable capitalization profile to Terns prior to acquisition and a similar model of developing differentiated targeted therapies. Both companies share a small-team, clinical-stage biotech operational profile.
  • Nuvalent: Nuvalent is a clinical-stage precision oncology biotech developing next-generation kinase inhibitors with novel binding modes — directly analogous to Terns' allosteric BCR::ABL1 approach with TERN-701. Both companies emphasize mechanism-based differentiation from approved kinase inhibitors.
  • Deciphera Pharmaceuticals: Deciphera was a clinical-stage small molecule oncology biotech that developed novel kinase inhibitors and was acquired by Bayer for ~$2.4B in 2021. Comparable development-stage model and kinase inhibitor focus to Terns, with prior strategic-acquisition precedent.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Terns Pharmaceuticals social profiles

Digital presence

Terns Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Terns Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles8 records

Terns Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Terns Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Terns Pharmaceuticals

What does Terns Pharmaceuticals do?

Terns Pharmaceuticals was a clinical-stage biopharmaceutical company developing a pipeline of oral small-molecule drug candidates targeting chronic myeloid leukemia (TERN-701, an allosteric BCR::ABL1 inhibitor), obesity (TERN-601, an oral GLP-1 receptor agonist), and metabolic dysfunction-associated steatohepatitis or MASH (TERN-501, a selective THR-β agonist, and TERN-101, a nonsteroidal FXR agonist). The company had no approved or commercially marketed products, with all candidates in investigational stages of clinical development.

Is Terns Pharmaceuticals a public or private company?

Terns Pharmaceuticals is a public company. It is classified as public and is currently acquired.

When was Terns Pharmaceuticals founded?

Terns Pharmaceuticals was founded in 2017. It employs 51 to 100 people.

Where is Terns Pharmaceuticals based?

Terns Pharmaceuticals is headquartered in Foster City, United States, in the North America region.

How does Terns Pharmaceuticals make money?

One revenue line is on record: pre-commercial Pipeline / No Revenue.

Who are Terns Pharmaceuticals's main competitors?

Direct peers on record are Novartis, Madrigal Pharmaceuticals and Akero Therapeutics. Broad incumbents are Eli Lilly and Pfizer. Emerging players are Structure Therapeutics, Viking Therapeutics, Syndax Pharmaceuticals, Nuvalent and Deciphera Pharmaceuticals.

Does Terns Pharmaceuticals have an API?

No public API is recorded for Terns Pharmaceuticals.

What industry is Terns Pharmaceuticals in?

Terns Pharmaceuticals's product category is Clinical-Stage Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics, with a secondary code of HLAIACAI, Hematology Specialty Pharmaceuticals (Non-malignant). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ChinaventureZhuhai State-owned Assets begins to harvest IPOs in bulk.Zhuhai Technology Industry Group, a state-owned enterprise formed by Huafa and Gree, has achieved 7 IPOs and 2 A+H listed companies in the first half of 2026. The group, with a 50 billion yuan registered capital, ranks among the top state-owned institutions in IPOs, second only to Shenzhen Capital Group, China International Capital Corporation, and Yida Capital.InvestorshangoutNever say goodbye too early, at - CYDY CytoDyn IncThe article analyzes the potential financing structure for a hypothetical $40–60 billion acquisition by Merck planned for 2027. It details a strategy involving bridge loans and permanent debt offerings to fund the deal, given Merck's limited cash reserves after recent expenditures on Cidara and Terns. The analysis highlights that such leverage would be aggressive but consistent with historical pharmaceutical M&A practices to offset the upcoming Keytruda patent cliff.The Motley FoolMerck (MRK) Q2 2026 Earnings Call TranscriptMerck & Co., Inc. reported Q2 2026 results, with revenues of $16.6 billion, marking a 4% growth fueled by strong demand in Oncology and Animal Health. The company completed a $6.8 billion acquisition of Terns Pharmaceuticals, resulting in a non-tax-deductible R&D charge of $5.7 billion. Merck raised its full year revenue guidance to a range of $66.3 billion to $67.3 billion, while emphasizing the potential of its pipeline which is projected to create over $70 billion in commercial opportunity.MorningstarHealth Care Down on Mixed Pharma Earnings — Health Care RoundupHealth-care companies declined as investors rotated out of defensive sectors into cyclical stocks following mixed earnings from major pharmaceutical companies. Pfizer beat Wall Street expectations with Q2 earnings driven by cancer and heart disease drug sales that offset declining Covid-19 product revenues, while Merck cut its full-year profit forecast due to one-off charges tied to its acquisition of cancer biotech Terns Pharmaceuticals. Shares of Danish obesity-drug maker Novo Nordisk also slid despite raising its annual revenue projection.pharmaphorumMSD records one hit, one miss with TL1A drug tulisokibartMSD reported that its anti-TL1A antibody tulisokibart met endpoints in a phase 2 trial for hidradenitis suppurativa but failed a study in systemic sclerosis-associated interstitial lung disease. The company's Q2 sales rose 5% to $16.6 billion, though a one-time charge from the Terns Pharma acquisition put it in a loss. MSD raised its 2026 revenue forecast to $66.3–$67.3 billion.BenzingaWhy Merck Just Slashed Its Profit Outlook By Nearly 50% - Merck & Co (NYSE:MRK)Merck & Co reported second-quarter adjusted losses of 13 cents per share, narrower than the expected 27-cent loss, with revenue rising 5% year over year to $16.61 billion, beating estimates, driven by Keytruda sales of $8.37 billion and strong growth in Winrevair. The company slashed its fiscal 2026 adjusted earnings guidance to $2.66–$2.76 per share from $5.04–$5.16, a reduction of nearly 50%, citing $3.62 per share in charges from the Cidara Therapeutics acquisition and $2.31 per share from the Terns acquisition. Merck simultaneously raised its revenue outlook to $66.3–$67.3 billion from the prior range of $65.8–$67.0 billion.Investing.comMerck Q2 2026 slides: portfolio transformation accelerates By Investing.comMerck & Co. reported Q2 2026 worldwide sales of $16.6 billion, up 5% nominally and 4% excluding foreign exchange, beating Wall Street earnings expectations despite a significant acquisition-related charge from the Terns Pharmaceuticals deal. The company's portfolio transformation strategy showed accelerating progress with launch product revenue reaching $1.5 billion, more than doubling from $0.6 billion in the prior-year quarter, while its pipeline advanced across multiple therapeutic areas including immunology, oncology, and cardiometabolic diseases. Merck raised its full-year 2026 revenue guidance to $66.3 billion to $67.3 billion, reflecting confidence in underlying business performance.Investing.comMerck Q2 2026 slides: pipeline gains accelerate portfolio transformation By Investing.comMerck & Co., Inc. presented its Q2 2026 results on August 4, 2026, reporting revenue of $16.6 billion (up 5% year-over-year) and a non-GAAP loss of $0.13 per share that beat analyst expectations of a $0.27 loss, driven by strong performance in oncology and animal health. The company achieved significant pipeline milestones including FDA approval of LIPFENDRA as the first oral PCSK9 inhibitor, positive Phase 3 results for sacituzumab tirumotecan in endometrial cancer, and positive topline data for islatravir/lenacapavir as a potential once-weekly oral HIV treatment. Merck completed the acquisition of Terns Pharmaceuticals during the quarter, which resulted in a $5.7 billion charge impacting reported earnings, leading the company to raise its revenue guidance to $66.3-$67.3 billion while lowering non-GAAP EPS guidance to $2.66-$2.76.MorningstarMerck Cuts Full-Year Profit Forecast as Acquisition Costs Weigh on Bottom LineMerck & Co. cut its full-year adjusted EPS guidance to $2.66-$2.76 from $5.04-$5.16, reflecting a $2.31 per-share one-time charge tied to its May acquisition of cancer biotech Terns Pharmaceuticals, along with 12 cents per share in financing and drug advancement costs. Despite the profit forecast reduction, Merck raised its full-year sales outlook to $66.3-$67.3 billion after second-quarter sales of $16.61 billion beat analyst expectations, driven by 5% growth in Keytruda revenue to $8.4 billion and strong launches from new products including Winrevair. The acquisition is part of Merck's strategy to expand its portfolio ahead of Keytruda's patent expiration, which will allow competitors to introduce lower-cost alternatives.Quiver QuantitativeMerck Posts $16.6 Billion Q2 Sales and GAAP Loss | MRK Stock NewsMerck & Co. reported Q2 2026 worldwide sales of $16.6 billion, a 5% increase year-over-year, though the company posted a GAAP net loss of $1.335 billion due to a $2.31-per-share charge related to its $6.8 billion acquisition of Terns Pharmaceuticals. The company raised its full-year 2026 sales guidance to $66.3–$67.3 billion and reported strong performance from KEYTRUDA ($8.4 billion) and WINREVAIR (75% growth to $588 million), alongside pipeline milestones including FDA approval of LIPFENDRA and positive Phase 3 data for an oral HIV treatment developed with Gilead.